A Phase 4 interventional study of Sublingual orally disintegrating olanzapine (SODO) and Oral olanzapine in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder, sponsored by Eli Lilly and Company. Completed at 21 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-06-10.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.
Among the 97 studies testing olanzapine in Schizophrenia, this one is the 36th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2006, is one of 46 in phase 4, and was the 37th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Centre for Addiction and Mental Health · Sites in Canada
Ages 18+
By country, each count listing its studies:
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 8 · Phase 3 25 · Phase 4 46
First in 1997; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 114 across the 94 interventional studies. Of the 86 that completed or were terminated, 25 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 97 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
33 studies in Schizophrenia by Eli Lilly and Company: 2 open now, 2 under way, none of them phase 3. Of 31 finished, 9 (29%) have results posted.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2006, is one of 16 in phase 4, and was the 17th registered.
Eli Lilly and Company’s Schizophrenia studies by the year they started, since 2001.
2 of the studies testing olanzapine in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781115University of ArizonaProposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia | 2027-02-10 |
| NCT04478838Centre for Addiction and Mental Health"Extended" (Alternate Day) Antipsychotic Dosing | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies testing olanzapine in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 33 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already gaining weight on olanzapine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Patients must NOT):
Sublingual orally disintegrating olanzapine (SODO)
Drug: Sublingual orally disintegrating olanzapine (SODO)
Oral olanzapine
Drug: Oral olanzapine
5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
Also known as: LY170053, Zydis
5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
Also known as: LY170053, Zyprexa
Time Course of Change From Baseline in Body Mass Index (BMI)
Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of changes at various time points throughout the study. Change = Time point value minus baseline (Visit 2) value.
Time frame: Visit 2 (Baseline) to Visit 7 (16 Weeks)
Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI)
Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of change from baseline to endpoint. Change = Endpoint (Week 16) minus Baseline (Week 0)
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) for the Treatment Completers
Body mass index is an estimate of body fat based on body weight divided by height squared. Comparisons of change from baseline to endpoint between participants who completed their treatment. Change = Endpoint value minus Baseline value.
Time frame: Visit 2 (Baseline) and Visit 7 (16 Weeks)
Mean Change From Baseline to 16 Week Endpoint in Weight
Weight of undressed patient (undergarments allowed), measured preferably at the same time each day.
Time frame: Visit 2 (Baseline) and Visit 7 (16 Weeks)
Mean Change From Baseline to 16 Week Endpoint in Waist Circumference
Waist circumference is measured on a bare abodomen just above the hip bone.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Number of Patients Achieving at Least 5% Loss of Body Weight in Any Post-Baseline Period
Percentage loss of body weight = 100\*(postbaseline weight - baseline weight)/baseline weight
Time frame: Visit 2 (Baseline) to Visit 7 (Week 16)
Number of Participants Discontinuing the Trial by Visit (Week)
The number of participants who discontinued by visit (non-cumulative).
Time frame: Visit 2 (Baseline) to Visit 7 (Week 16)
Change From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale
Participant chooses where they think their appetite lies on a 10 centimeter line between two anchors (0 - very poor appetite and 10 - very strong appetite). The possible range of scores is 0 to 100 and represents millimeters on the 10 centimeter line.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in Blood Pressure
Sitting blood pressure, taken from the same arm.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in Fasting Lipoproteins (Total Cholesterol, High-Density Lipoprotein Cholesterol [HDL-Cholesterol], Low-Density Lipoprotein Cholesterol [LDL-Cholesterol] [Calculated], and Triglycerides)
Patients should be fasting a minimum of eight hours prior to lipoprotein measurements.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Change From Baseline to 16 Week Endpoint in Fasting Plasma Glucose
Patients should be fasting a minimum of eight hours prior to plasma glucose measurement.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin
Patients should be fasting a minimum of eight hours prior to serum insulin measurement.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated)
HOMA-S is an estimate of insulin sensitivity. The HOMA model is a computer model of the glucose insulin feedback system in the fasted state. The model consists of a number of non-linear empirical equations describing the functions of organs and tissues involved in glucose regulation.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Number of Participants Meeting a Definition for the Presence of Metabolic Syndrome as Defined by Adult Treatment Panel III (ATP III) Criteria at Baseline and 16 Week Endpoint
Patient meets definition of metabolic syndrome if they have \>=3 risk factors: Waist circumference (men\>102cm, women\>88cm); triglycerides \>=1.7mmol/L; HDL cholesterol (men\<1.04mmol/L, women\<1.30mmol/L); blood pressure \>135/\>=85 mmHg; Fasting glucose \>=6.1mmol/L
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale
Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale
Measures subjective well-being for previous 7 days. 20 items covering 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). Subscale scores range from 1 to 24. Total score ranges from 1 to 120.
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
Mean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale
Measures physician's judgment of a patient's overall level of functioning. Ratings are based on a scale of 1 to 100, with the following classification range: 1-10 (severely impaired) to 91-100 (superior functioning).
Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)
| Milestone | SODO | SOT |
|---|---|---|
| Started | 84 | 65 |
| Completed | 65 | 50 |
| Not completed | 19 | 15 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Lost to follow-up | 5 | 2 |
| Withdrew: Protocol entry criteria not met | 2 | 2 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Noncompliance | 2 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of changes at various time points throughout the study. Change = Time point value minus baseline (Visit 2) value.
| kilograms/square meters | SODO | SOT |
|---|---|---|
| Week 2 (N=82, N=63) | 0.09 ± 0.06 | 0.16 ± 0.07 |
| Week 4 (N=79, N=63) | 0.25 ± 0.08 | 0.27 ± 0.09 |
| Week 8 (N=75, N=58) | 0.34 ± 0.12 | 0.32 ± 0.13 |
| Week 12 (N=70, N=54) | 0.47 ± 0.16 | 0.54 ± 0.18 |
| Week 16 (N=67, N=51) | 0.52 ± 0.18 | 0.72 ± 0.20 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of change from baseline to endpoint. Change = Endpoint (Week 16) minus Baseline (Week 0)
| kilograms/square meters | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) | 0.52 ± 1.49 | 0.67 ± 1.44 |
Body mass index is an estimate of body fat based on body weight divided by height squared. Comparisons of change from baseline to endpoint between participants who completed their treatment. Change = Endpoint value minus Baseline value.
| kilograms/square meters | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) for the Treatment Completers | 0.56 ± 1.59 | 0.79 ± 1.58 |
Weight of undressed patient (undergarments allowed), measured preferably at the same time each day.
| kilograms | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in Weight | 1.42 ± 0.50 | 2.08 ± 0.57 |
Waist circumference is measured on a bare abodomen just above the hip bone.
| centimeters | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in Waist Circumference | 1.13 ± 5.25 | 0.77 ± 5.30 |
Percentage loss of body weight = 100\*(postbaseline weight - baseline weight)/baseline weight
| participants | SODO | SOT |
|---|---|---|
| Up to Week 2 (N=82, N=63) | 0 | 0 |
| Up to Week 4 (N=79, N=63) | 0 | 1 |
| Up to Week 8 (N=75, N=58) | 2 | 2 |
| Up to Week 12 (N=70, N=54) | 3 | 4 |
| Up to Week 16 (N=67, N=51) | 4 | 6 |
The number of participants who discontinued by visit (non-cumulative).
| participants | SODO | SOT |
|---|---|---|
| Visit 3 (Week 2) Discontinuations | 3 | 1 |
| Visit 4 (Week 4) Discontinuations | 3 | 1 |
| Visit 5 (Week 8) Discontinuations | 5 | 6 |
| Visit 6 (Week 12) Discontinuations | 5 | 6 |
| Visit 7 (Week 16) Discontinuations | 3 | 1 |
Participant chooses where they think their appetite lies on a 10 centimeter line between two anchors (0 - very poor appetite and 10 - very strong appetite). The possible range of scores is 0 to 100 and represents millimeters on the 10 centimeter line.
| units on a scale | SODO | SOT |
|---|---|---|
| Change From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale | -8.21 ± 2.26 | -5.02 ± 2.59 |
Sitting blood pressure, taken from the same arm.
| mm Hg | SODO | SOT |
|---|---|---|
| Systolic Blood Pressure | 0.1 ± 11.62 | -0.1 ± 10.83 |
| Diastolic Blood Pressure | 0.3 ± 7.55 | 0.8 ± 8.35 |
Patients should be fasting a minimum of eight hours prior to lipoprotein measurements.
| millimole/Liter | SODO | SOT |
|---|---|---|
| Total Cholesterol | 0.1 ± 0.74 | 0.2 ± 0.79 |
| High-Density Lipoprotein Cholesterol | -0.0 ± 0.24 | -0.0 ± 0.24 |
| Low-Density Lipoprotein Cholesterol (N=73, N=57) | 0.1 ± 0.66 | 0.2 ± 0.53 |
| Triglycerides | 0.1 ± 0.84 | 0.0 ± 1.01 |
Patients should be fasting a minimum of eight hours prior to plasma glucose measurement.
| millimole/Liter | SODO | SOT |
|---|---|---|
| Change From Baseline to 16 Week Endpoint in Fasting Plasma Glucose | 0.2 ± 0.79 | 0.1 ± 0.48 |
Patients should be fasting a minimum of eight hours prior to serum insulin measurement.
| microIU/milliliter | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin | 2.4 ± 17.72 | -0.1 ± 5.52 |
| percent | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin | 0.0 ± 0.24 | 0.0 ± 0.28 |
HOMA-S is an estimate of insulin sensitivity. The HOMA model is a computer model of the glucose insulin feedback system in the fasted state. The model consists of a number of non-linear empirical equations describing the functions of organs and tissues involved in glucose regulation.
| percent sensitivity | SODO | SOT |
|---|---|---|
| Mean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated) | -18.5 ± 58.91 | -9.8 ± 62.61 |
Patient meets definition of metabolic syndrome if they have \>=3 risk factors: Waist circumference (men\>102cm, women\>88cm); triglycerides \>=1.7mmol/L; HDL cholesterol (men\<1.04mmol/L, women\<1.30mmol/L); blood pressure \>135/\>=85 mmHg; Fasting glucose \>=6.1mmol/L
| participants | SODO | SOT |
|---|---|---|
| Baseline - Metabolic Syndrome (N=82, N=65) | 18 | 16 |
| Endpoint - Metabolic Syndrome (N=70, N=52) | 18 | 10 |
Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale | -0.26 ± 0.07 | -0.09 ± 0.08 |
Measures subjective well-being for previous 7 days. 20 items covering 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). Subscale scores range from 1 to 24. Total score ranges from 1 to 120.
| units on a scale | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale | 4.79 ± 1.52 | 1.60 ± 1.73 |
Measures physician's judgment of a patient's overall level of functioning. Ratings are based on a scale of 1 to 100, with the following classification range: 1-10 (severely impaired) to 91-100 (superior functioning).
| units on a scale | SODO | SOT |
|---|---|---|
| Mean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale | 4.61 ± 1.05 | 2.72 ± 1.20 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SODO | — | — | — |
| SOT | — | — | — |
| Event | SODO | SOT |
|---|---|---|
| DizzinessNervous system disorders | 1/84 | 0/65 |
| Suicide attemptPsychiatric disorders | 1/84 | 0/65 |
| Event | SODO | SOT |
|---|---|---|
| Increased appetiteMetabolism and nutrition disorders | 9/84 | 10/65 |
| FatigueGeneral disorders | 3/84 | 5/65 |
| HeadacheNervous system disorders | 5/84 | 5/65 |
| SomnolenceNervous system disorders | 5/84 | 5/65 |
| DizzinessNervous system disorders | 0/84 | 4/65 |
| NasopharyngitisInfections and infestations | 1/84 | 3/65 |
| InsomniaPsychiatric disorders | 2/84 | 3/65 |
| ConstipationGastrointestinal disorders | 3/84 | 1/65 |
| Decreased appetiteMetabolism and nutrition disorders | 3/84 | 0/65 |
| AnxietyPsychiatric disorders | 3/84 | 2/65 |
| Age Continuous(years) | SODO | SOT | Total |
|---|---|---|---|
| Mean | 38.6 ± 13.13 | 38.7 ± 12.23 | 38.6 ± 12.7 |
| Sex: Female, Male(Participants) | SODO | SOT | Total |
|---|---|---|---|
| Female | 36 | 32 | 68 |
| Male | 48 | 33 | 81 |
| Region of Enrollment(participants) | SODO | SOT | Total |
|---|---|---|---|
| United States | 23 | 18 | 41 |
| Mexico | 27 | 23 | 50 |
| Canada | 29 | 21 | 50 |
| Netherlands | 5 | 3 | 8 |
| Presence of Metabolic Syndrome(participants) | SODO | SOT | Total |
|---|---|---|---|
| No | 64 | 49 | 113 |
| Yes | 18 | 16 | 34 |
| Unknown | 2 | 0 | 2 |
| Psychiatric Illness(participants) | SODO | SOT | Total |
|---|---|---|---|
| Schizophrenia | 46 | 36 | 82 |
| Schizophreniform | 7 | 2 | 9 |
| Schizoaffective disorder | 3 | 12 | 15 |
| Other related psychiatric disorder | 1 | 1 | 2 |
| Bipolar disorder | 27 | 14 | 41 |
| Race/Ethnicity(participants) | SODO | SOT | Total |
|---|---|---|---|
| African Descent | 11 | 4 | 15 |
| Caucasian | 42 | 36 | 78 |
| East/Southeast Asian | 2 | 1 | 3 |
| First Nations | 2 | 0 | 2 |
| Hispanic | 27 | 23 | 50 |
| Other | 0 | 1 | 1 |
| Blood Pressure(mm Hg) | SODO | SOT | Total |
|---|---|---|---|
| Systolic Blood Pressure | 120.3 ± 16.45 | 119.0 ± 12.49 | 119.7 ± 14.82 |
| Diastolic Blood Pressure | 77.6 ± 9.62 | 75.8 ± 9.15 | 76.8 ± 9.43 |
| Body Mass Index(kilograms/meters-squared) | SODO | SOT | Total |
|---|---|---|---|
| Mean | 28.0 ± 5.63 | 28.3 ± 4.76 | 28.1 ± 5.26 |
11 further baseline measures are reported on the registry.
The record gives a start of Mar 2006, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine